Recognition and Management of Sleep-Disordered Breathing in Chronic Heart Failure
- First Online:
- Cite this article as:
- Kahwash, R., Kikta, D. & Khayat, R. Curr Heart Fail Rep (2011) 8: 72. doi:10.1007/s11897-010-0037-1
- 79 Downloads
It is increasingly recognized that sleep-disordered breathing (SDB) is a common modifiable risk factor for cardiovascular disease with significant impact on morbidity and potentially mortality. SDB is highly prevalent in patients with systolic or diastolic heart failure. A high index of suspicion is necessary to diagnose SDB in patients with heart failure because the vast majority of affected patients do not report daytime symptoms. Recent clinical trials have demonstrated improvement in heart function, exercise tolerance, and quality of life after treatment of SDB in patients with heart failure. Accumulating evidence suggests that treatment of SDB should complement the established pharmacologic therapy for chronic heart failure. However, mortality benefit has yet to be demonstrated.